Absci Corp (ABSI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Absci Corp (ABSI) has a cash flow conversion efficiency ratio of -0.153x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-26.31 Million) by net assets ($171.97 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ABSI equity financing ratio to measure how much of total assets are equity-financed.
Absci Corp - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Absci Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Absci Corp cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Absci Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Absci Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aker Biomarine AS
OL:AKBM
|
-0.046x |
|
ZHEJIANG ASIA-PACIFIC MECHANICAL & ELECTRONIC CO LTD
SHE:002284
|
0.060x |
|
Akcansa Cimento Sanayi ve Ticaret AS
IS:AKCNS
|
0.041x |
|
Oil-Dri Corporation Of America
NYSE:ODC
|
0.077x |
|
Revolve Group LLC
NYSE:RVLV
|
0.024x |
|
Chang Wah Electromaterials Inc
TW:8070
|
0.037x |
|
Henan Yicheng New Energy Co Ltd
SHE:300080
|
-0.019x |
|
Shenzhen Laibao High-Technology Co Ltd
SHE:002106
|
0.017x |
Annual Cash Flow Conversion Efficiency for Absci Corp (2019–2025)
The table below shows the annual cash flow conversion efficiency of Absci Corp from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see Absci Corp (ABSI) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $189.45 Million | $-92.92 Million | -0.491x | -21.36% |
| 2024-12-31 | $179.13 Million | $-72.40 Million | -0.404x | -10.17% |
| 2023-12-31 | $176.18 Million | $-64.64 Million | -0.367x | -23.78% |
| 2022-12-31 | $274.41 Million | $-81.34 Million | -0.296x | -79.08% |
| 2021-12-31 | $366.11 Million | $-60.60 Million | -0.166x | -1.10% |
| 2020-12-31 | $67.00 Million | $-10.97 Million | -0.164x | -211.71% |
| 2019-12-31 | $-41.16 Million | $-6.03 Million | 0.147x | -- |
About Absci Corp
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the… Read more